Published in Gene Therapy Weekly, December 11th, 2003
According to a study from Czech Republic, "the jet-injection technology was used for delivery of recombinant adeno-associated virus (rAAV). Although AAV-based vectors are an attractive tool in gene therapy, some methodological and technical problems of their targeted delivery remain to be solved. We tried to address some of these cell-targeting problems by using a new low-volume needleless injection device, the Swiss Injector."
"First, we tested by electron microscopy whether jet-injection would have any detrimental effect on rAAV particle integrity. Second, we compared...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.